Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. 18 years and older and ambulatory (defined as able to walk at least 10 meters);~  2. Clinical diagnosis of symptomatic orthostatic hypotension associated with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency;~  3. At the Baseline visit (Visit 2), patients must demonstrate:~ 1. a score of at least 4 or greater on the Orthostatic Hypotension Symptom Assessment (OHSA) Item #1;~ 2. a fall of at least 20 mmHg in their systolic blood pressure, within 3 minutes of standing;~     4. Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care;~     Exclusion Criteria:~* 1. Score of 23 or lower on the mini-mental state examination (MMSE);~  2. Concomitant use of vasoconstricting agents for the purpose of increasing blood pressure;~ 1. Patients taking vasoconstricting agents such as ephedrine, dihydroergotamine, or midodrine must stop taking these drugs at least 2 days or 5 half-lives (whichever is longer) prior to their baseline visit (Visit 2) and throughout the duration of the study;~     3. Known or suspected alcohol or substance abuse within the past 12 months (DSM-IV definition of alcohol or substance abuse);~     4. Women who are pregnant or breastfeeding;~     5. Women of child bearing potential (WOCP) who are not using at least one method of contraception with their partner;~     6. Male patients who are sexually active with a woman of child bearing potential (WOCP) and not using at least one method of contraception;~     7. Untreated closed angle glaucoma;~     8. Diagnosis of hypertension that requires treatment with antihypertensive medications (short-acting antihypertensives to treat nocturnal supine HTN are allowed in this study) Any significant uncontrolled cardiac arrhythmia;~     9. History of myocardial infarction, within the past 2 years;~     10. Current unstable angina;~     11. Congestive heart failure (NYHA Class 3 or 4);~     12. History of cancer within the past 2 years other than a successfully treated, non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in situ;~     13. Gastrointestinal condition that may affect the absorption of study drug (e.g. ulcerative colitis, gastric bypass);~     14. Any major surgical procedure within 30 days prior to the Baseline visit (Visit 2);~     15. Previously treated with droxidopa within 30 days prior to the Baseline visit (Visit 2);~     16. Currently receiving any other investigational drug or have received an investigational drug within 30 days prior to the Baseline visit (Visit 2);~     17. Any condition or laboratory test result, which in the Investigator's judgment, might result in an increased risk to the patient, or would affect their participation in the study;~     18. The Investigator has the ability to exclude a patient if for any reason they feel the subject is not a good candidate for the study or will not be able to follow study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Droxidopa (Type: ACTIVE_COMPARATOR): Droxidopa 100 mg, 200 mg, 300 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).